NKTR
Nektar TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Rezpegaldesleukin has now produced supportive AD and AA data, the company says Phase 3 AD starts in Q2 2026, and the February financing materially improved near-term flexibility [#IR-2026-03-28] [#10-K-2026-03-13].
Posture
Defensive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-03.
What can break
2026 operating cash burn rises faster than investors expect despite the February raise and ATM proceeds
Momentum
17
Value
41
Sentiment
77
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $78.00 · Bull $105.00 · Bear $52.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bearish
Target $129.86
Why
Momentum17 · Δ7d -22.7
Value41 · Δ7d +0.0
Sentiment77 · Δ7d +14.8
So what
Weak posture (Net Bearish). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
17
34% active weight
Current posture
7d trendSoftening
Δ7d
-22.7
Δ21d
-73.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
77
33% active weight
Current posture
7d trendImproving
Δ7d
+14.8
Δ21d
+40.6
Why this grade
Composite grade D. Momentum 16.8 / Value 41.1 / Sentiment 76.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.98B
Beta
1.35
Shares Out
20.34M
P/E (TTM) · Derived
-8.4
P/S (TTM)
14.45
P/FCF (TTM) · Derived
-7.80
Rev YoY
-51.1%
EPS YoY
+29.4%
Gross Margin
+87.3%
Op Margin
-156.7%
Net Debt
-$163.45M
Current Ratio
4.24
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology